This paper examines the relations between Apoliprotein B, Apoliprotein A1 and Diabetes Type 2.
Diabetes mellitus refers to a group of metabolic disorders of multiple aetiology and characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.
The effects of diabetes mellitus include long–term damage, dysfunction and failure of various organs. Diabetes mellitus may present with characteristic symptoms such as thirst, polyuria, blurring of vision, and weight loss. In its most severe forms, ketoacidosis or a non–ketotic hyperosmolar state may develop and lead to stupor, coma and in absence of effective treatment, death.
Often symptoms are not severe, or may be absent, and consequently hyperglycaemia sufficient to cause pathological and functional changes may be present for a long time before the diagnosis is made. It is a major health problem in all nations. Diabetes is the single, most important metabolic disease, widely recognized as one of the leading causes of death and disability worldwide.
This devastating disease can affect nearly every system in the body. It can cause blindness, lead to end stage renal disease, lower extremity amputations and increase the risk for stroke, ischemic heart disease, peripheral vascular disease, and neuropathy. Diabetic macro and microvascular complications are resulting in increased disability and enormous health care costs.
Table of Contents
Apoliprotein B, A1 and Diabetes Type 2
Classification of Diabetes
Prediabetes
Feature of IFG/ IGT
Pathophysiology of Prediabetes
Natural history of type 2 diabetes
Clinical significance of prediabetes
Risk for Cardiovascular disease
APOLIPOPROTEINS
Apolipoprotein A1
Effect of glucose and insulin on ApoA1 gene expression
Effect of insulin resistance on ApoA1 expression
Apolipoprotein B
Insulin and apolipoproteins
Research Objectives and Core Themes
The primary objective of this work is to elucidate the complex metabolic interplay between insulin resistance, the regulation of apolipoproteins (specifically ApoA1 and ApoB), and the pathogenesis of Type 2 diabetes and associated cardiovascular risks. It explores the transcriptional control mechanisms and signaling pathways that modulate lipoprotein expression under both normal and diabetic metabolic conditions.
- Pathophysiology of prediabetes and progression to Type 2 diabetes.
- Molecular regulation of ApoA1 gene expression by insulin and metabolic signals.
- Role of insulin resistance in driving VLDL-ApoB overproduction and dyslipidemia.
- Clinical significance of apolipoprotein ratios as markers for cardiovascular risk.
Excerpt from the Book
Apolipoprotein A1
ApoA1 is the major apo in HDL-c particles and initiates the ‘reverse cholesterol transport’. ApoA1 can ‘pick up’ excess cholesterol from peripheral cells and transfer it back to the liver in the HDL particles. ApoA1 also manifests anti-inflammatory and antioxidant effects (Walldius and Jungner, 2004; Marcovina and Packard, 2006; Schlitt et al., 2005; Shah et al., 2001; Barter and Rye, 2006). ApoA1 is not contained in the potentially atherogenic ApoB-containing particles and thus ApoA1 in most cases only reflects the athero-protective part of the metabolism. ApoA1 is considered to be the ‘active ingredient’ in HDL. It mediates cell–lipoprotein interactions, and is essential for cholesterol uptake into the lipoprotein and for deposition of the lipid in hepatocytes via the agency of SR-B1-like receptors (Rye et al., 1999, Lewis and Rader, 2005). The protein also has anti-inflammatory and anti-oxidative properties and this may contribute to its cardioprotective role as inflammation and oxidation are believed to be key processes in atherosclerosis. HDL-c particles are smaller and contain different apolipoproteins, mainly apoA1 and apoA-II. Both these apolipoproteins have properties that protect the lipids against oxidative modification. In addition, some of the other proteins transported by HDL, such as paraoxonase, have antioxidant properties. Therefore, whereas LDL is very susceptible to oxidative modification, HDL-c is relatively resistant to it, and this is one of the reasons underlying the anti-inflammatory properties of HDL (Rye et al., 1999).
Summary of Chapters
Apoliprotein B, A1 and Diabetes Type 2: Provides an introduction to the global health burden of diabetes, its classification, and the clinical definition of prediabetic states.
Classification of Diabetes: Outlines the four main classes of the disease and defines the clinical stages of Impaired Glucose Tolerance and Impaired Fasting Glycaemia.
Prediabetes: Details the natural history, pathophysiological mechanisms, and the associated risks of progression to overt diabetes and cardiovascular disease.
APOLIPOPROTEINS: Introduces the protein components of lipoproteins and their critical functions in lipid transport and removal from circulation.
Apolipoprotein A1: Examines the role of ApoA1 in reverse cholesterol transport and the specific factors influencing its gene expression through signaling pathways like Sp1.
Apolipoprotein B: Discusses the structure and metabolism of ApoB, specifically its role in VLDL-ApoB overproduction in insulin-resistant states.
Insulin and apolipoproteins: Analyzes the adverse effects of hyperinsulinemia and insulin insensitivity on apolipoprotein levels and the resulting clinical implications.
Keywords
Diabetes Mellitus, Type 2 Diabetes, Prediabetes, Insulin Resistance, Hyperinsulinemia, Apolipoprotein A1, Apolipoprotein B, HDL, VLDL, Dyslipidemia, Cardiovascular Disease, Reverse Cholesterol Transport, Sp1, Metabolic Disorder, Lipoprotein Lipase.
Frequently Asked Questions
What is the core focus of this publication?
The text fundamentally investigates the metabolic disorder of Diabetes Mellitus, with a specific focus on how insulin resistance impacts the regulation and function of apolipoproteins A1 and B.
What are the primary themes discussed?
Central themes include the classification of diabetes, the transition from prediabetes to Type 2 diabetes, the molecular mechanisms of lipoprotein synthesis, and the correlation between dyslipidemia and cardiovascular health.
What is the main research objective?
The goal is to understand how metabolic signaling pathways, particularly those involving insulin, contribute to the pathological changes in apolipoprotein levels observed in diabetic patients.
Which scientific methodology is highlighted?
The work utilizes a comprehensive review of existing clinical and biochemical studies, focusing on transcriptional control, gene expression analysis, and metabolic pathway modeling.
What topics are covered in the main body?
The main sections cover the pathophysiology of prediabetes, the structural biology of LDL and HDL, the influence of glucose/insulin on ApoA1, and the regulation of ApoB in insulin-resistant subjects.
What are the key descriptive terms for this work?
Important keywords include insulin resistance, hyperglycemia, ApoA1, ApoB, cardiovascular risk, reverse cholesterol transport, and metabolic dysfunction.
How does insulin resistance influence VLDL production?
The work explains that insulin resistance impairs the negative regulation of VLDL assembly, leading to increased hepatic VLDL production and, subsequently, higher levels of circulating VLDL-ApoB.
Why is the ApoB/ApoA1 ratio clinically relevant?
The ratio serves as a refined marker for cardiovascular risk, as it balances the pro-atherogenic nature of ApoB-containing particles against the protective, anti-atherogenic role of ApoA1.
- Quote paper
- Reaz Mazumdar (Author), 2008, Apoliprotein B, A1 and Diabetes Type 2, Munich, GRIN Verlag, https://www.grin.com/document/338391
